Chronic Kidney Disease Trial, Recruiting NCT04098354 Sponsor: University of Alberta Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT04098354
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have a confirmed diagnosis of chronic kidney disease (CKD) that is not being treated with dialysis, with kidney function or protein levels in the urine that meet specific medical thresholds (confirm with trial site)
  • People who live in remote areas within the Peace River region of Alberta, Canada
  • People who have been diagnosed with high blood pressure by a doctor, or who report having it and are currently taking medication to manage it
  • People who own a smartphone (iPhone or Android) with access to a wireless internet connection
  • People who can read, write, and speak English, and who are willing and able to give their consent to take part in the trial
  • People who are willing and able to regularly use a home blood pressure tracking device, with at least 80% of recordings successfully sent during a training period

Who may not be able to join:

  • People found to have a dangerously high blood pressure crisis during the training period
  • People with very advanced CKD (the most severe stage, stage 5) or those already receiving kidney replacement therapy such as dialysis or a transplant
  • People who have heart failure where the heart's pumping ability is significantly reduced
  • People with a terminal illness where life expectancy is less than one year
  • People currently taking part in another clinical drug trial
  • People who are pregnant or breastfeeding
  • People who are planning to move out of the Peace River region, or who live in an area without mobile phone coverage

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aminu Bello, University of Alberta

Phone: 17807098964

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 April 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Effectiveness of telemonitoring and protocol-based case management versus usual care:

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov